What It Is
KPV is one of the shortest peptides studied for potential therapeutic relevance: a tripeptide made of lysine, proline, and valine. It corresponds to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone peptide long studied for its role in immune and inflammatory signaling.[2]
Because it shares this fragment with alpha-MSH, KPV is discussed almost entirely within anti-inflammatory peptide research rather than as a growth-hormone-related or metabolic compound. It is not a therapeutic protein or an approved drug; it is a small research molecule whose biological interest comes from a mechanistic link to melanocortin biology rather than from any clinical track record of its own.
How It Works
KPV's proposed activity centers on dampening inflammatory signaling, particularly through pathways involving NF-kB, a transcription-factor system that helps switch on genes involved in the body's inflammatory response.[5] In intestinal research, KPV uptake has been linked to a transporter called PEPT1, which moves small peptides like KPV across the cells lining the gut wall, offering one possible route for oral or local delivery.[3]
These are cellular-level observations, not proof of a clinical effect. A peptide that quiets an inflammatory signal in a lab dish or an animal model of colitis does not automatically translate into meaningful symptom relief, disease remission, or safety in a person with a chronic inflammatory condition.
What the Research Shows
The most cited KPV research is a 2008 study reporting that PEPT1-mediated uptake of the tripeptide reduced intestinal inflammation in experimental cell and mouse colitis models.[3] Related work has examined KPV and alpha-MSH-derived fragments in laboratory and animal systems relevant to skin inflammation, wound healing, and cytokine signaling.[2] This evidence is useful for generating hypotheses, not for establishing a treatment.
Human clinical evidence is absent. In its 2026 source review, FDA found no clinical studies, case reports, or human exposure data for KPV administered by any route.[17] KPV is not an established treatment for inflammatory bowel disease, psoriasis, dermatitis, wound healing, or any other condition.
Safety & Side Effects
KPV has no FDA-approved label and no human safety database. FDA found no human exposure data, no clinical safety studies, and no adverse-event case reports through its reviewed sources; because exposure itself is uncharacterized, the absence of reports cannot be interpreted as safety.[17]
Potential risks remain unknown, including immunogenicity and aggregation, local or systemic reactions, long-term effects, pregnancy and lactation risk, and interactions with immune-modulating medicines. Unapproved or compounded products add separate identity, impurity, concentration, and sterility risks.[18]
Regulatory Status
KPV is not an FDA-approved drug and has no approved indication or human dosage.[10] At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA evaluated KPV free base and acetate for wound healing and inflammatory conditions.[16] Its briefing proposed not adding either substance to the 503A Bulks List because of poor characterization and the absence of human safety or effectiveness information.[17]
That proposal is part of the advisory process, not an approval. Experimental cell or animal exposures are not clinically validated human doses, and a compounded or "research" label does not establish product equivalence or safety.